Your browser doesn't support javascript.
loading
Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study.
Evans, Alison; Davies, Miranda; Osborne, Vicki; Roy, Debabrata; Shakir, Saad.
Afiliação
  • Evans A; Drug Safety Research Unit, Southampton, United Kingdom.
  • Davies M; University of Portsmouth, Portsmouth, United Kingdom.
  • Osborne V; Drug Safety Research Unit, Southampton, United Kingdom.
  • Roy D; University of Portsmouth, Portsmouth, United Kingdom.
  • Shakir S; Drug Safety Research Unit, Southampton, United Kingdom.
PLoS One ; 15(10): e0240489, 2020.
Article em En | MEDLINE | ID: mdl-33035259
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Acidente Vascular Cerebral / Inibidores do Fator Xa / Rivaroxabana / Hemorragia Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Acidente Vascular Cerebral / Inibidores do Fator Xa / Rivaroxabana / Hemorragia Idioma: En Ano de publicação: 2020 Tipo de documento: Article